KLRF2 Inhibitors
Chemical inhibitors of KLRF2 engage in a variety of interactions that result in the functional inhibition of this protein. Cyclosporin A, through its immunosuppressive action, inhibits calcineurin which would ordinarily be downstream of T-cell activation pathways where KLRF2 may be implicated. The binding of Cyclosporin A to the cyclophilins and the subsequent inhibition of IL-2 production can lead to a reduced T-cell activation, thus indirectly affecting the functioning of KLRF2. Another compound, Dasatinib, operates as a tyrosine kinase inhibitor and obstructs BCR-ABL and Src family kinases, which are involved in signaling pathways that likely intersect with KLRF2's role. Similarly, PP2, as an Src family kinase inhibitor, would disrupt signaling pathways essential for the function of immune cells where KLRF2 is potentially active.
Rapamycin and Wortmannin both act on the mTOR and PI3K/AKT pathways respectively, crucial for cell proliferation and survival. Rapamycin's inhibition of mTOR can reduce the activity of cellular processes involving KLRF2, while Wortmannin's inhibition of PI3K disrupts AKT/mTOR signaling, both leading to an indirect functional inhibition of KLRF2. Ly294002, another PI3K inhibitor, similarly disrupts the AKT/mTOR pathway. U0126 and PD98059, which are MEK inhibitors, and SB203580, a p38 MAPK inhibitor, interfere with the MAPK pathways. By preventing the activation of MEK1/2 and p38 MAPK, these inhibitors can impede cellular processes that require MAPK/ERK signaling, where KLRF2 may be involved. SP600125 targets JNK, part of the MAPK signaling pathways, and its inhibition could disrupt pathways necessary for KLRF2's function. Lastly, Sorafenib and Imatinib, which are multi-kinase inhibitors, target various kinases within different signaling pathways. Sorafenib's targeting of RAF kinases and Imatinib's inhibition of BCR-ABL, c-KIT, and PDGFR can lead to the disruption of signaling cascades necessary for the function of immune cells, and thereby, the functional inhibition of KLRF2.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A is an immunosuppressant that binds to the cyclophilins. This complex inhibits calcineurin which is downstream of T-cell activation pathways that KLRF2 is potentially associated with, leading to the inhibition of IL-2 production and T-cell activation that could indirectly inhibit the function of KLRF2 by reducing the immune response where KLRF2 might be acting. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and Src family kinases. These kinases are involved in multiple signaling pathways, including those that could engage KLRF2, and by inhibiting these kinases, Dasatinib could impede the signaling pathways in which KLRF2 may play a role, leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. The mTOR pathway is critical for cell cycle progression and proliferation. By inhibiting mTOR, Rapamycin can reduce the activity of cellular processes where KLRF2 may be involved, especially in immune cells, leading to indirect functional inhibition of KLRF2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Ly294002 is a PI3K inhibitor, and PI3K is involved in the AKT/mTOR signaling pathway. As PI3K activity is inhibited, downstream signaling including mTOR is disrupted, which can indirectly lead to the functional inhibition of KLRF2 by impeding cellular processes in which KLRF2 is involved. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinase inhibitor. By inhibiting Src kinases, PP2 could impede the signaling pathways that are necessary for the function of immune cells where KLRF2 is potentially active, leading to its indirect functional inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. By inhibiting MEK1/2, U0126 can block the ERK pathway, potentially leading to the functional inhibition of KLRF2 by impeding cellular processes that require MAPK/ERK signaling where KLRF2 may be involved. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By blocking p38 MAPK, it can disrupt the signaling pathways that are important for stress responses and cytokine production where KLRF2 could be active, leading to indirect functional inhibition of KLRF2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor, specifically blocking MEK1 which is upstream in the MAPK/ERK pathway. Inhibition of MEK1 by PD98059 could lead to functional inhibition of KLRF2 by disrupting the signaling pathways necessary for cellular processes where KLRF2 may be involved. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathways. JNK is involved in controlling a number of cellular processes including immune cell function. By inhibiting JNK, SP600125 could indirectly functionally inhibit KLRF2 by disrupting pathways necessary for its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. By inhibiting PI3K, Wortmannin can disrupt the AKT/mTOR pathway, leading to indirect functional inhibition of KLRF2 by impeding the signaling required for immune cell activities where KLRF2 may be active. | ||||||